{"id":"ofatumumab-combined-with-daratumumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201836","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ofatumumab is a fully human anti-CD20 monoclonal antibody that binds to CD20 expressed on B cells and induces B-cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Daratumumab is an anti-CD38 monoclonal antibody that targets CD38 on plasma cells and malignant B cells, inducing apoptosis and immune activation. The combination leverages dual targeting of complementary antigens to enhance anti-tumor efficacy in hematologic malignancies.","oneSentence":"Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:57.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination regimens)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ofatumumab combined with daratumumab","genericName":"Ofatumumab combined with daratumumab","companyName":"The First People's Hospital of Changzhou","companyId":"the-first-people-s-hospital-of-changzhou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ofatumumab and daratumumab are monoclonal antibodies that work synergistically to target and eliminate malignant B cells and plasma cells by binding to CD20 and CD38 respectively, triggering immune-mediated cell death. Used for Multiple myeloma (in combination regimens), Chronic lymphocytic leukemia (CLL), B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}